GC Green Cross Wellbeing, 'Lynex Placenta Injection for Liver Function Improvement' First Administered in China

GC Green Cross Wellbeing's placenta injection product, Lynek, has been administered for the first time in China.

GC Green Cross Wellbeing announced on the 17th that the first administration of Lynek began on the 16th. Lynek is the first placenta injection product from South Korea approved in China, having received expedited approval last month in the Boao Lecheng Pilot Zone, Hainan Province.

Lynek is an injection made from placentas collected in obstetrics and gynecology. It is a pharmaceutical product approved to improve liver function in patients with chronic liver disease. In particular, it lowers the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are indicators of liver disease symptoms, and has excellent efficacy in liver cell regeneration, showing superior therapeutic effects for patients with alcoholic fatty liver and non-alcoholic fatty liver disease.

Following the first patient administration, GC Green Cross Wellbeing plans to establish sales strategies to enable more liver disease patients to receive Lynek by providing education about Lynek to hospital specialists within the region.

Meanwhile, the Boao Lecheng Pilot Zone, where the first administration took place, is designated as an international medical tourism pilot zone and is the only medical special zone in China. In 2013, the Chinese State Council approved the establishment of the Boao Lecheng International Medical Tourism Pilot Zone, and through a series of special preferential policies, it allows the special import and approval of international pharmaceuticals and medical devices.

A GC Green Cross Wellbeing official stated, “Lynek is already a product recording 38 billion KRW annually in the domestic market,” and added, “With the approval in Hainan Province and the start of administration, we plan to distribute it throughout China after obtaining approval from the National Medical Products Administration (NMPA) by 2026 through separate clinical trials.”

This content was produced with the assistance of AI translation services.